Preclinical evaluation and first in human study of Al18F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer

• DOI: 10.3389/fonc.2022.1030187
• Publication Date: 2022-10-20T11:34:24Z
• Authors: Ya’nan Ren; Chen Liu; Teli Liu; Xiaojiang Duan; Qian Zhang; Jiayue Liu; Pei Wang; Qian Guo; Xing Yang; Peng Du; Hua Zhu; Zhi Yang
• Keywords: Pulmonary and Respiratory Medicine; clinical translational; Radiology, Nuclear Medicine and Imaging; Positron emission tomography; oxalyldiaminopropionic acid-urea (ODAP-Urea) ligand; Cancer research; Biochemistry; Role of Fibroblast Activation in Cancer Progression; 03 medical and health sciences; Advancements in Prostate Cancer Research; Biodistribution; 0302 clinical medicine; In vitro; Glutamate carboxypeptidase II; Health Sciences; Alpha Particle Therapy; In vivo; PSMA; Internal medicine; Biology; RC254-282; Cancer; Prostate cancer; LNCaP; Prostate; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Development and Applications of Radiopharmaceuticals; prostate cancer; PET Imaging; 3. Good health; Chemistry; Oncology; Nuclear medicine; Medicine; [18F]AlF2+; Imaging agent; Biotechnology

PurposeThis study aimed to introduce a novel [18F]AlF-labeled ODAP-Urea-based Prostate-specific membrane antigen (PSMA) probe, named [18F]AlF-PSMA-137, which was derived from the successful modification of glutamate-like functional group. The preclinically physical and biological characteristics of the probe were analyzed. Polit clinical PET/CT translation was performed to analyze its feasibility in clinical diagnosis of prostate cancer.Methods[18F]AlF-PSMA-137 was maturely labeled with the [18F]AlF2+ labeling technique. It was analyzed by radio-HPLC for radiochemical purity and stability analysis in vitro and in vivo. The PSMA specificity was investigated in PSMA-positive (LNCaP) and PSMA-negative (PC3) cells, and the binding affinity was evaluated in LNCaP cells. Micro-PET/CT imaging was performed in mice bearing LNCaP or PC3 tumors. Thirteen patients with newly diagnosed prostate cancer were included for [18F]AlF-PSMA-137 PET/CT imaging. Physiologic biodistribution and tumor burden were semi-quantitatively evaluated and the radiation dosimetry of [18F]AlF-PSMA-137 was estimated.ResultsThe radiochemical yield of [18F]AlF-PSMA-137 was 54.2 ± 10.7% (n = 16) with the radiochemical purity over 99% and the specific activity of 26.36 ± 7.33 GBq/μmol. The binding affinity to PSMA was 2.11 ± 0.63 nM. [18F]AlF-PSMA-137 showed high cell/tumor uptake which can be specifically blocked by PSMA inhibitor. According to the biodistribution in patients, [18F]AlF-PSMA-137 was mainly accumulated in kidneys, lacrimal glands, parotid glands, submandibular glands and liver which was similar to the extensive Glu-Ureas based probes. A total of 81 lesions were detected in PET/CT imaging and over 91% of lesions increased between 1 h p.i. (SUVmean: 10.98 ± 18.12) and 2 h p.i. (SUVmean: 14.25 ± 21.28) (p < 0.001). Additionally, the probe showed intensive accumulation in lesions which provided excellent imaging contrast with the high tumor-to-muscle ratio of 15.57 ± 27.21 at 1 h p.i. and 25.42 ± 36.60 at 2 h p.i. (p < 0.001), respectively. The effective dose of [18F]AlF-PSMA-137 was estimated as 0.0119 ± 0.0009 mSv/MBq.ConclusionAn ODAP-Urea-based PSMA probe [18F]AlF-PSMA-137 was successfully prepared with high specificity and binding affinity to PSMA. Micro-PET/CT imaging study demonstrated its feasibility for prostate cancer imaging. Pilot clinical study showed its potential for delay-imaging and prostate cancer detection.